SLC5A2 and hydrops fetalis: In the wider context of the five studies of 21,947 participating individuals, the SGLT2 inhibitors mitigated the risk of composite CV mortality or hospitalization for HF (HR 0.77), CV mortality (HR 0.87), first hospitalization for HF (0.72) and all-cause mortality (HR 0.92).